Guardian Pharmacy Services, Inc.

GRDN Healthcare Medical Care Facilities

Guardian Pharmacy Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.9% from fiscal 2024.

Revenue
−1.68%
EPS
+133.3%
Free cash flow
+88.9%

Quarter to September 2026, against a year earlier

39.72 2.37 −5.63%
Market cap
$2.5B
P/E
37.8×
Fwd P/E
33.3×
Dividend yield
—
F-score
7/9
Altman Z
10.28
Beneish M
−2.95
Dividend safety
n/a

Insider Decisions last twelve months

Bought, $m 0.10
Sold, $m 419.26
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 1 — — — — — — — — — — —
Sell — — — 9 — — — — — — — —
Insider Ownership 66.73%

Capital & Financial Ratios $m

Size
Market Cap 2,530.00
Revenue ttm 1,457.05
Net income ttm 76.05
Free cash flow ttm 114.06
Net debt Q (119.65)
Valuation
P/E 37.83 (above 35: high)
Forward P/E 33.30
Price / sales 1.73
Forward P/S Powerpack
Price / FCF 26.48
Price / book 8.99 (above 6: high)
Financial health
Current ratio Q 1.65 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 141.60
Growth
Revenue growth Q −1.68% (below 0%: shrinking)
Operating income growth Q +53.25% (above 0%: growing)
EPS, this year +22.75% (at or above 15%: strong)
EPS, next year A +9.90%
Revenue, next year A −0.46% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +14.35%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 5 66 120
Receivables 77 97 102 108
Inventory 37 41 43 57
Other 15 10 11 10
130 152 222 295
2023 2024 2025 Q'26
Payables 86 102 116 126
ST’ Debt 9 — — —
Other 16 20 22 25
138 144 161 179

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Earnings Trends EPS, adjusted, against the consensus

EPS $

Mar Jun Sep Dec Year
’26 0.21 0.34 — — —
’25 0.15 0.14 0.15 0.33 0.78
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 337 352 371 — —
’25 329 344 377 398 1,449
’24 275 300 314 339 1,228
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 6 30 43 — —
’25 18 20 28 35 100
’24 9 29 (2) 22 58
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 25 43 — —
’25 12 16 23 30 81
’24 5 26 (7) 18 42
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — 1,046 1,228 1,449 1,457 +17.7% 1,442 1,533 1,681 +5.1%
Gross margin, % — — — — — — — 19.91 19.89 20.21 22.45 +0.3 pt
EBT — — — — — — — 38 (66) 73 105 +39.5%
EBT margin, % — — — — — — — 3.61 (5.41) 5.07 7.22 +1.5 pt
Net income — — — — — — — 38 (71) 49 76 +13.9%
Per share, $
Per share, $ Revenue — — — — — — — 0.00 19.81 23.22 0.00 n/m
Earnings — — — — — — — — (1.77) 0.79 1.05 n/m
Cash flow — — — — — — — 0.00 0.93 1.61 0.00 n/m
Capex — — — — — — — 0.00 (0.26) (0.31) (0.30) n/m
Free cash flow — — — — — — — 0.00 0.67 1.29 0.00 n/m
Book value — — — — — — — 0.00 2.42 3.49 0.00 n/m
Shares, m — — — — — — — 0 62 62 63 n/m
Valuation, ×
Valuation, × P/E — — — — — — — 0.00 0.00 38.09 37.83 12.7
P/S — — — — — — — 0.00 1.02 1.30 1.73 0.8
P/B — — — — — — — 0.00 8.38 8.61 8.99 5.7
EV/Sales — — — — — — — 0.00 1.05 1.28 1.67 0.8
EV/FCF — — — — — — — 0.00 31.02 22.92 25.63 18.0
Cash, $m
Cash, $m Operating cash flow — — — — — — — 71 58 100 114 +19.0%
Capex — — — — — — — (15) (16) (20) (19) +15.9%
Free cash flow — — — — — — — 56 42 81 114 +19.8%
Balance, $m
Balance, $m Working capital — — — — — — — (8) 8 61 116 n/m
Net debt — — — — — — — 27 (5) (66) (120) n/m
Shareholders’ equity — — — — — — — 60 150 218 280 +90.8%
Returns, %
Returns, % ROA — — — — — — — — (37.18) 13.42 16.96 +50.6 pt
ROIC — — — — — — — 29.38 (27.06) 29.83 36.76 +0.5 pt
ROE — — — — — — — — (104.89) 26.76 31.47 +131.7 pt
People
People Employees — — — — — — — 3,200 3,400 3,600 — +6.1%
Revenue/emp, $m — — — — — — — 0.33 0.36 0.40 — +10.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Guardian Pharmacy Services, Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NHC National HealthCare Corporation $3.3B 28.2× 8.4× +6.61% (above 0%: growing) −65.61% (below 0%: shrinking) +75.52% (above 0%: growing) 100.00% 0.00% Compare
ACHC Acadia Healthcare Company, Inc. $3.2B — (loss-making) 34.4× +5.14% (above 0%: growing) −5.00% (below 0%: shrinking) +196.54% (above 0%: growing) 100.00% 0.00% Compare
SGRY Surgery Partners, Inc. $3.0B — (loss-making) — (loss-making) +2.75% (above 0%: growing) n/m −60.63% (below 0%: shrinking) 22.41% 12.78% Compare
AVAH Aveanna Healthcare Holdings Inc. $3.0B 10.5× 18.3× +13.73% (above 0%: growing) +46.15% (above 0%: growing) +57.89% (above 0%: growing) 32.59% 11.93% Compare
BKD Brookdale Senior Living Inc. $2.6B — (loss-making) 341× −11.61% (below 0%: shrinking) n/m +533.14% (above 0%: growing) 29.94% 11.86% Compare
GRDN Guardian Pharmacy Services, Inc. $2.5B 37.8× 33.3× −1.68% (below 0%: shrinking) +133.33% (above 0%: growing) +88.88% (above 0%: growing) 22.97% 6.75%
MD Pediatrix Medical Group, Inc. $2.5B 17.1× 15.3× +1.72% (above 0%: growing) −27.61% (below 0%: shrinking) −14.41% (below 0%: shrinking) 27.98% 13.01% Compare
ADUS Addus HomeCare Corporation $2.4B 21.1× 20.3× +7.02% (above 0%: growing) +24.19% (above 0%: growing) −17.07% (below 0%: shrinking) 32.08% 10.27% Compare
ASTH Astrana Health, Inc. $1.9B 46.8× 25.9× +48.52% (above 0%: growing) +110.53% (above 0%: growing) −67.74% (below 0%: shrinking) 10.70% 3.53% Compare
Median of peers $2.8B 21.1× 20.3× +5.88% +9.60% +21.74% 31.01% 11.07%

All 51 Medical Care Facilities stocks →

Pay and ownership Proxy statement filed 26 March 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 845.84k 845.84k 188.00
2024 766.10k 766.10k 127.00
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Guardian Pharmacy Services, Inc. (GRDN) Latest News

13 Aug

Impact 3 · · The Motley Fool transcript

22 Jun

GRDN metrics, ten years each

stockrow.com/GRDN · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com